ARTICLE | Company News
Perjeta sales and marketing update
December 2, 2016 5:14 PM UTC
The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Perjeta pertuzumab from Roche in combination with the pharma’s Herceptin trastuzumab and docetaxel for neoadjuvant...
BCIQ Company Profiles
BCIQ Target Profiles
Epidermal growth factor (EGF) receptor 2 (HER2) (ErbB2) (neu)